https://orcid.org/0000-0002-1638-6214
Figures & data
Figure 1. Epidemiology of HFMD since 2010.
Table 1. Summary of the research and development of the CV-A6 vaccine
Figure 2. The genotyping of the 15 CV-A6 vaccine and detection candidate strains used in this study. The ML tree analysis revealed that the prototype Gdula strain belongs to genotype A, while the 13 CV-A6 strains belong to subgenotype D3, and the XM strain belongs to subgenotype D1. The names of these strains are indicated in the figure.
Figure 3. Cross-neutralizing capacity of the plasma from humans naturally infected with CV-A6 and the sera from murine immunized with CV-A6. A: The GMTs of 30 human plasma against various strains of CV-A6 ranged from 18.1 to112.2. The difference among the GMTs for genotype A, subgenotype D1, and C3 strains ranged from 1.0–6.2-folds (shown with a blue bar). B: The GMTs of 15 murine sera against various strains ranged from 63.8–886.8, of which the discrepancy among all strains was 1.5–13.9-fold (shown with an orange bar).
Table 2. List of CV-A6 strains.
Table 3. Comparison of serum cross-neutralization capacities after setting the value of serum neutralization against the corresponding virus strain to 100.
Figure 4. Cross-neutralization ability of sera from murine inoculated with CV-A6 strains. Fifteen sera were collected after inoculating murine with 15 CV-A6 strains separately. CV-A6 NtAb titer < 8 (Log2 Scale < 3) was considered negative, while CV-A6 NtAb titer ≥ 8 (Log2 Scale ≥ 3) was considered positive.
Figure 5. Cross protective effect of anti-S110 against lethal challenge of 5 CV-A6 strains. Anti-S110 (48-fold dilution) showed a good protective effect against 5 CV-A6 strains, and it ascended from 67% to 100% in the order S110, Gdula, S112, S102, and S101.
Table 4. Cross-protection of anti-S110 against the lethal challenge of five CV-A6 strains.